A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
Elena ValassiAnna AulinasCamilla Am GladGudmundur JohannssonOskar RagnarssonSusan M WebbPublished in: Clinical endocrinology (2017)
A polymorphism in the CYP17A1 gene was associated with the response to steroidogenesis inhibitors in CS. Genetic differences in the steroidogenic enzymes might account for inter-individual variations in the responsiveness to adrenal-blocking agents.